
The FDA approved bepirovirsen (Hibsago; GSK) with nucleos(t)ide analogue therapy for chronic hepatitis B, based on B-Well 1 and 2 functional cure rates of 19% vs 0% with placebo.
Charitha Gowda, MD, MPH, discusses the current and upcoming methods to prevent hepatitis C.
Charitha Gowda, MD, MPH, infectious diseases physician at Penn Presbyterian Medical Center, discusses the current and upcoming methods to prevent hepatitis C.






